Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed

NCT00047333 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

80

Enrollment

NIH

Sponsor class

Stopped Administratively complete.

Conditions

Adult Primary Hepatocellular Carcinoma
Advanced Adult Primary Liver Cancer
Localized Unresectable Adult Primary Liver Cancer

Interventions

DRUG: erlotinib hydrochloride
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)